The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies

Infection and Immunity

Volumn 85, Issue 12, 2017, Pages

  Wang Lin, Shun Xin ^a   Olson, Ruth ^b,c   Beanan, Janet M ^b,c   MacDonald, Ulrike ^b,c   Balthasar, Joseph P ^a   Russo, Thomas A ^b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acinetobacter baumannii; Capsule polysaccharide; Monoclonal antibody; Outer membrane protein A; Passive immunization

Indexed keywords

BACTERIAL POLYSACCHARIDE; COMPLEMENT; MONOCLONAL ANTIBODY; OUTER MEMBRANE PROTEIN A; BACTERIUM ANTIBODY; OMPA OUTER MEMBRANE PROTEINS; OUTER MEMBRANE PROTEIN; PROTEIN BINDING;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIGEN BINDING; ARTICLE; ASCITES; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; GRAM NEGATIVE SEPSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; ANIMAL; DISEASE MODEL; IMMUNOLOGY; METABOLISM; SEPSIS; SERUM BACTERICIDAL ACTIVITY; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTERIAL OUTER MEMBRANE PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; MICE; POLYSACCHARIDES, BACTERIAL; PROTEIN BINDING; SEPSIS; TREATMENT OUTCOME;

EID: 85034042159     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00591-17     Document Type: Article

References (33)

1. Michalopoulos A, Falagas ME. 2010. Treatment of Acinetobacter infections. Expert Opin Pharmacother 11:779-788. https://doi.org/10.1517/ 14656561003596350
2. Spellberg B, Rex JH. 2013. The value of single-pathogen antibacterial agents. Nat Rev Drug Discov 12:963. https://doi.org/10.1038/nrd3957-c1
3. March GA, Bratos MA. 2015. A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii. J Microbiol Methods 119:31-36. https://doi.org/10.1016/j.mimet.2015.09.014
4. Manchanda V, Sanchaita S, Singh N. 2010. Multidrug resistant acinetobacter. J Glob Infect Dis 2:291-304. https://doi.org/10.4103/0974-777X.68538
5. Shlaes DM, Sahm D, Opiela C, Spellberg B. 2013. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 57:4605-4607. https://doi.org/10.1128/AAC.01277-13
6. Howard A, O'Donoghue M, Feeney A, Sleator RD. 2012. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 3:243-250. https://doi.org/10.4161/viru.19700
7. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012 Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
8. Park WH. 1931. Serum therapy. Bull N Y Acad Med 7:401-411
9. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. 2012. Active and passive immunization protects against lethal, extreme drug-resistant Acinetobacter baumannii infection. PLoS One 7:e29446. https://doi.org/10.1371/journal.pone.0029446
10. Zhang X, Yang T, Cao J, Sun J, Dai W, Zhang L. 2016. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb Pathog 96:20-25. https://doi.org/10.1016/j.micpath.2016.04.019
11. Huang W, Yao Y, Wang S, Xia Y, Yang X, Long Q, Sun W, Liu C, Li Y, Chu X, Bai H, Yao Y, Ma Y. 2016. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci Rep 6:20724. https://doi.org/10.1038/srep20724
12. McConnell MJ, Dominguez-Herrera J, Smani Y, Lopez-Rojas R, Docobo-Perez F, Pachon J. 2011. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun 79:518-526. https://doi.org/10.1128/IAI.00741-10
13. Casadevall A. 1996. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 2:200-208. https://doi.org/10.3201/eid0203.960306
14. Felton LD. 1928. The units of protective antibody in antipneumococcus serum and antibody solution. J Infect Dis 43:531-542. https://doi.org/10.1093/infdis/43.6.531
15. Weisman LE, Cruess DF, Fischer GW. 1994. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. 13: 1122-1125
16. Slade HB. 1994. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1:613-619
17. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. 2010. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 78:704-715. https://doi.org/10.1128/IAI.00881-09
18. Russo TA, Beanan JM, Olson R, MacDonald U, Cope JJ. 2009. Capsular polysaccharide and the O-specific antigen impede antibody binding: a potential obstacle for the successful development of an extraintestinal pathogenic Escherichia coli vaccine. Vaccine 27:388-395. https://doi.org/10.1016/j.vaccine.2008.10.082
19. Pluschke G, Mayden J, Achtman M, Levine RP. 1983. Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun 42:907-913
20. van der Ley P, Kuipers O, Tommassen J, Lugtenberg B. 1986. O-antigenic chains of lipopolysaccharide prevent binding of antibody molecules to an outer membrane pore protein in Enterobacteriaceae. Microb Pathog 1:43-49. https://doi.org/10.1016/0882-4010(86)90030-6
21. Kenyon JJ, Hall RM. 2013. Variation in the complex carbohydrate biosynthesis loci of Acinetobacter baumannii genomes. PLoS One 8:e62160. https://doi.org/10.1371/journal.pone.0062160
22. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 78:3993-4000. https://doi.org/10.1128/IAI.00366-10
23. Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. 2013. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 81:915-922. https://doi.org/10.1128/IAI.01184-12
24. Russo TA, MacDonald U, Beanan JM, Olson R, MacDonald IJ, Sauberan SL, Luke NR, Schultz LW, Umland TC. 2009. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumannii in vitro and in vivo. J Infect Dis 199:513-521. https://doi.org/10.1086/596317
25. Hesterkamp T. 2016. Antibiotics clinical development and pipeline. Curr Top Microbiol Immunol 398:447-474. https://doi.org/10.1007/82_2015 _451
26. Butler MS, Blaskovich MA, Cooper MA. 2017. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot 70:3-24. https://doi.org/10.1038/ ja.2016.72
27. Geisinger E, Isberg RR. 2015. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog 11:e1004691. https://doi.org/10.1371/journal.ppat.1004691
28. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. 2017. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev 30:409-447
29. Nwodo UU, Green E, Okoh AI. 2012. Bacterial exopolysaccharides: functionality and prospects. Int J Mol Sci 13:14002-14015. https://doi.org/10.3390/ijms131114002
30. Kennett RH. 1979. Cell fusion. Methods Enzymol 58:345-359. https://doi.org/10.1016/S0076-6879(79)58149-X
31. Tayab ZR, Balthasar JP. 2004. Development and validation of enzymelinked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. J Immunoassay Immunochem 25:335-344. https://doi.org/10.1081/IAS-200033830
32. Cuenca FF, Pascual A, Martinez Marinez L, Conejo MC, Perea EJ. 2003. Evaluation of SDS-polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of Acinetobacter baumannii. J Basic Microbiol 43:194-201. https://doi.org/10.1002/jobm.200390022
33. Hobb RI, Fields JA, Burns CM, Thompson SA. 2009. Evaluation of procedures for outer membrane isolation from Campylobacter jejuni. Microbiology 155:979-988. https://doi.org/10.1099/mic.0.024539-0